Biohaven presents new migraine data at 64th annual scientific meeting of the american headache society, including first of its kind study for nurtec® odt (rimegepant), and complete phase 3 data for zavegepant nasal spray

-  nurtec odt open-label extension study is the first of its kind evaluating a cgrp-targeted medication in patients who are using it as a preventive and an as-needed acute treatment for migraine -  over the course of this open-label extension study, > 80% of patients experienced ≥50% reduction and approximately 50% experienced a 100% reduction -  complete data from the phase 3 zavegepant nasal spray study highlight its ultra-rapid pain relief in as little as 15 minutes that lasts through 48 hours after a single dose -  new studies showed positive efficacy, safety and pharmacokinetics data for nurtec odt as an acute treatment of migraine in adults from china and korea new haven, conn. , june 13, 2022 /prnewswire/ -- biohaven pharmaceutical holding company ltd.
BHVN Ratings Summary
BHVN Quant Ranking